Ambamustine HCl
Code | Size | Price |
---|
TAR-T2507L-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2507L-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Ambamustine HCl is a novel tripeptide anticancer.
CAS:
83996-50-3
Molecular Weight:
666.08
Purity:
0.98
SMILES:
N(CCCl)(CCCl)C1=CC(C[C@@H](C(N[C@H](C(OCC)=O)CCSC)=O)NC([C@H](CC2=CC=C(F)C=C2)N)=O)=CC=C1.Cl
References
Ambamustine. PTT119. Drugs R D. 2003;4(2):119-21. PubMed PMID: 12718568.
Manna A, Porcellini A, Visani G, Marchetti-Rossi MT, Tura S. Limiting dilution analysis of a novel tripeptide anticancer agent Ambamustine (PTT-119): effect on K-562, CCRF-SB and multidrug resistant LoVo-Dk cell lines. Exp Hematol. 1994 Jun;22(6):517-20. PubMed PMID: 8187848.
Mattii L, Barale R, Petrini M. Use of the comet test in the evaluation of multidrug resistance of human cell lines. Leukemia. 1998 Apr;12(4):627-32. PubMed PMID: 9557624.
Ardizzoni A, Antonelli G, Ricci S, Frasci G, Rinaldi M, Boni L, Galletti P, Pennucci MC, Antonuzzo A, Gravina A, Galli L, Comella G, Conte PF, Salvati F, Rosso R. Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap study. Am J Clin Oncol. 2000 Feb;23(1):22-5. PubMed PMID: 10683068.